Physician profile
Andrew Daya
NPI 1679987390
$9,801.11
in general payments reported to CMS, 2019-2025
37 companies · $2,965 in 2025
The $2,965 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,637 · 2020: $759 · 2021: $508 · 2022: $68.63 · 2023: $1,889 · 2024: $1,975 · 2025: $2,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,041 · Education: $638 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,040.64 |
| Education | $637.94 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,721.65 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Jazz Pharmaceuticals INC. | $1,512.67 | 2022-2025 | |
| Glaxosmithkline, LLC. | $1,313.87 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Harmony Biosciences LLC | $856.02 | 2023-2025 | Wakix |
| Abiomed | $616.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.23 | 2020-2025 | Ofev, Jascayd, Stiolto Respimat |
| Genzyme Corporation | $396.58 | 2023-2025 | |
| Inspire Medical Systems, INC. | $294.84 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $253.10 | 2023-2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $249.99 | 2021 | |
| Genentech USA, INC. | $218.21 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $207.33 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Verona Pharma, INC. | $195.84 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $152.43 | 2020-2021 | |
| United Therapeutics Corporation | $147.31 | 2019-2025 | Tyvaso, Tyvaso |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $145.88 | 2019 | |
| Mallinckrodt Hospital Products INC. | $133.34 | 2020-2025 | Acthar |
| Grifols USA, LLC | $110.33 | 2025 | Prolastin-C Liquid |
| Amgen INC. | $95.84 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $93.57 | 2023-2025 | Aralast, Glassia |
| Insmed, INC. | $89.89 | 2023-2024 | Arikayce |
| Lilly USA, LLC | $79.60 | 2025 | Zepbound |
| Boston Scientific Corporation | $57.86 | 2020-2021 | |
| Mylan Specialty L.P. | $52.19 | 2023-2024 | Yupelri |
| Electromed, INC. | $49.53 | 2025 | Smartvest |
| Vifor Pharma, INC. | $40.22 | 2025 | Zemaira |
| Axsome Therapeutics, INC. | $34.36 | 2023 | Sunosi |
| Philips North America LLC | $34.09 | 2023-2024 | (Ak6) Vest Therapy |
| Novartis Pharmaceuticals Corporation | $27.85 | 2019 | |
| Viatris Specialty LLC | $22.61 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $22.51 | 2024 | Purified Cortrophin Gel |
| Circassia INC. | $17.92 | 2019 | |
| Resmed Corp | $15.19 | 2023 | |
| Watermark Medical, INC. | $13.87 | 2024 | |
| Novo Nordisk INC | $13.68 | 2020 | |
| Sandoz INC. | $12.39 | 2019 | |
| Erbe USA INC | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Daya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.